Corona Remedies IPO Analyzed

This analysis summarizes the initial public offering (IPO) of Corona Remedies, a pharmaceutical company focused on women’s health and related areas. The IPO performance and key factors surrounding the company offer valuable insights for investors. Understanding these details is crucial for assessing the company’s potential.

Key Points

• IPO received 28.17 million bids versus 45.71 million shares offered.
• The IPO was subscribed 0.62 times, indicating moderate investor interest.
• The IPO raised Rs 194.85 crore from anchor investors before launch.
• Corona Remedies holds 72.5% of the company’s shares post-IPO.
• Revenue is primarily driven by women’s healthcare and cardio-diabeto.
• Strong regional presence in Western India contributes to significant sales.

The IPO was for the sale of shares worth Rs 655.37 crore. Bids were received for 28,17,234 shares, significantly fewer than the 45,71,882 shares initially offered. The issue was only partially subscribed at 0.62 times, suggesting investors might be hesitant at the current price range.

Corona Remedies is a domestic company operating primarily in India. It concentrates on developing, manufacturing, and marketing pharmaceutical products. Their core therapeutic areas include women’s healthcare, cardio-diabeto, pain management, urology, and other areas. A substantial portion – approximately 53.19% – of their revenue comes from women’s healthcare and cardio-diabeto in the first quarter of fiscal year 2026 (Q1 FY26).

As of June 30, 2025, the company boasts a diverse portfolio of 71 brands spanning these therapeutic areas, alongside multispecialty pharmaceuticals including vitamins, minerals, and nutrition (VMN), gastrointestinal, and respiratory products. India accounts for 96.34% of their revenue, with exports making up just 3.66%.

The company has a strong regional presence, especially in the western zone of India – Gujarat, Maharashtra, Goa, Madhya Pradesh, and Chhattisgarh. Ahead of the IPO, Corona Remedies successfully raised Rs 194.85 crore by allotting 18.34 lakh shares to 17 anchor investors at a price of Rs 1,062 each on December 5, 2025.

For the three months ending September 30, 2025, Corona Remedies recorded a consolidated net profit of Rs 46.20 crore and total sales of Rs 346.54 crore, demonstrating solid financial performance.

Ultimately, the IPO’s limited subscription rate suggests a need for continued investor education and a clearer understanding of Corona Remedies’ growth potential.